Proprietary AI analyst is now available

Sangamo Therapeutics Valuation Multiples

Discover Sangamo Therapeutics' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Annovis Bio, Rein Therapeutics, Heron Therapeutics, Dongkoo Bio&Pharma Co and more.

Sangamo Therapeutics Overview

About Sangamo Therapeutics

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington’s Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.


Founded

1995

HQ

United States

Employees

183

Financials (LTM)

Revenue: $40M
EBITDA: ($112M)

EV

$66M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Sangamo Therapeutics Financials

Sangamo Therapeutics reported last 12-month revenue of $40M and negative EBITDA of ($112M).

In the same LTM period, Sangamo Therapeutics generated $39M in gross profit, ($112M) in EBITDA losses, and had net loss of ($114M).

Revenue (LTM)


Sangamo Therapeutics P&L

In the most recent fiscal year, Sangamo Therapeutics reported revenue of $40M and EBITDA of ($100M).

Sangamo Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of (254%) and net margin of (311%).

See analyst estimates for Sangamo Therapeutics
LTMLast FY202320242025202620272028
Revenue$40M$40M$176M$58M$40M
Gross Profit$39M---$40M
Gross Margin97%---100%
EBITDA($112M)($100M)($97M)($89M)($100M)
EBITDA Margin(279%)(254%)(55%)(154%)(254%)
EBIT Margin(280%)(273%)(68%)(170%)(273%)
Net Profit($114M)($123M)($258M)($98M)($123M)
Net Margin(285%)(311%)(146%)(169%)(311%)

Financial data powered by Morningstar, Inc.

Sangamo Therapeutics Stock Performance

Sangamo Therapeutics has current market cap of $74M, and enterprise value of $66M.

Market Cap Evolution


Sangamo Therapeutics' stock price is $0.18.

Sangamo Therapeutics share price decreased by 67.0% in the last year.

Sangamo Therapeutics has an EPS (earnings per share) of $-0.30.

See more trading valuation data for Sangamo Therapeutics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$66M$74M5.0%--27.7%-67.0%$-0.30

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Sangamo Therapeutics Valuation Multiples

Sangamo Therapeutics trades at 1.6x EV/Revenue multiple, and (0.6x) EV/EBITDA.

See NTM and 2027E valuation multiples for Sangamo Therapeutics

EV / Revenue (LTM)


Sangamo Therapeutics Financial Valuation Multiples

As of June 18, 2026, Sangamo Therapeutics has market cap of $74M and EV of $66M.

Sangamo Therapeutics has a P/E ratio of (0.6x).

LTMLast FY202320242025202620272028
EV/Revenue1.6x1.7x0.4x1.1x1.7x
EV/EBITDA(0.6x)(0.7x)(0.7x)(0.7x)(0.7x)
EV/EBIT(0.6x)(0.6x)(0.6x)(0.7x)(0.6x)
EV/Gross Profit1.7x---1.7x
P/E(0.6x)(0.6x)(0.3x)(0.8x)(0.6x)
EV/FCF-(0.7x)(0.3x)(1.0x)(0.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Sangamo Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Sangamo Therapeutics Margins & Growth Rates

Sangamo Therapeutics grew revenue by 3% and EBITDA by 5% in the last fiscal year.

In the most recent fiscal year, Sangamo Therapeutics reported EBITDA margin of (254%) and net margin of (311%).

See estimated margins and future growth rates for Sangamo Therapeutics

Sangamo Therapeutics Margins

Last FY202420252026202720282029
Gross Margin--100%93%
EBITDA Margin(254%)(154%)(254%)(259%)
EBIT Margin(273%)(170%)(273%)(264%)
Net Margin(311%)(169%)(311%)(256%)
FCF Margin(246%)(117%)(246%)-

Sangamo Therapeutics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth3%(67%)(32%)3%
Gross Profit Growth---(5%)
EBITDA Growth5%(8%)13%5%
EBIT Growth(1%)(17%)10%(1%)
Net Profit Growth(16%)(62%)26%(16%)
FCF Growth-(73%)44%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Sangamo Therapeutics Operational KPIs

Sangamo Therapeutics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.8M for the same period.

Sangamo Therapeutics' Rule of 40 is (256%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sangamo Therapeutics' Rule of X is (252%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Sangamo Therapeutics
LTMLast FY202320242025202620272028
Rule of 40(175%)(256%)---
Bessemer Rule of X(18%)(252%)---
Revenue per Employee-$0.2M---
Opex per Employee-$0.8M---
G&A Expenses to Revenue-88%35%77%88%
R&D Expenses to Revenue285%285%133%193%285%
Opex to Revenue-373%168%270%373%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Sangamo Therapeutics Competitors

Sangamo Therapeutics competitors include Annovis Bio, Rein Therapeutics, Heron Therapeutics, Dongkoo Bio&Pharma Co, Pliant Therapeutics, Replek, Adicet Bio, XBiotech, Gain Therapeutics and Lytix Biopharma.

Most Sangamo Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Annovis Bio--(2.0x)(1.2x)
Rein Therapeutics--(3.4x)-
Heron Therapeutics1.1x1.1x11.6x11.6x
Dongkoo Bio&Pharma Co0.8x-2.7x-
Pliant Therapeutics--0.5x0.6x
Replek2.2x-11.1x-
Adicet Bio--0.4x-
XBiotech--2.1x-

This data is available for Pro users. Sign up to see all Sangamo Therapeutics competitors and their valuation data.

Start Free Trial

Acquisitions by Sangamo Therapeutics

Sangamo Therapeutics has acquired 1 company to date.

Last acquisition by Sangamo Therapeutics was on July 23rd 2018. Sangamo Therapeutics acquired TxCell for $78M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Sangamo Therapeutics

TxCell
Description
TxCell is a Sophia Antipolis-based biopharma company developing Tr1 cell therapies for autoimmune diseases including Crohn's and rheumatoid arthritis. The ENTRALLY platform targets refractory patients, with Phase II trials completed in Europe showing 50% response rates. Spun out from Inserm in 2007, TxCell collaborates with Takeda and operates GMP facilities in France.
HQ CountryFrance
HQ City
Nice
Deal Date23 Jul 2018
Valuation$78M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Sangamo Therapeutics acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Sangamo Therapeutics

When was Sangamo Therapeutics founded?Sangamo Therapeutics was founded in 1995.
Where is Sangamo Therapeutics headquartered?Sangamo Therapeutics is headquartered in United States.
How many employees does Sangamo Therapeutics have?As of today, Sangamo Therapeutics has over 183 employees.
Who is the CEO of Sangamo Therapeutics?Sangamo Therapeutics' CEO is Alexander Donald Macrae.
Is Sangamo Therapeutics publicly listed?Yes, Sangamo Therapeutics is a public company listed on OTCM.
What is the stock symbol of Sangamo Therapeutics?Sangamo Therapeutics trades under SGMO ticker.
When did Sangamo Therapeutics go public?Sangamo Therapeutics went public in 2000.
Who are competitors of Sangamo Therapeutics?Sangamo Therapeutics main competitors include Annovis Bio, Rein Therapeutics, Heron Therapeutics, Dongkoo Bio&Pharma Co, Pliant Therapeutics, Replek, Adicet Bio, XBiotech, Gain Therapeutics, Lytix Biopharma.
What is the current market cap of Sangamo Therapeutics?Sangamo Therapeutics' current market cap is $74M.
What is the current revenue of Sangamo Therapeutics?Sangamo Therapeutics' last 12 months revenue is $40M.
What is the current revenue growth of Sangamo Therapeutics?Sangamo Therapeutics revenue growth (NTM/LTM) is 104%.
What is the current EV/Revenue multiple of Sangamo Therapeutics?Current revenue multiple of Sangamo Therapeutics is 1.6x.
Is Sangamo Therapeutics profitable?No, Sangamo Therapeutics is not profitable.
What is the current EBITDA of Sangamo Therapeutics?Sangamo Therapeutics has negative EBITDA and is not profitable.
What is Sangamo Therapeutics' EBITDA margin?Sangamo Therapeutics' last 12 months EBITDA margin is (279%).
What is the current EV/EBITDA multiple of Sangamo Therapeutics?Current EBITDA multiple of Sangamo Therapeutics is (0.6x).
How many companies Sangamo Therapeutics has acquired to date?As of June 2026, Sangamo Therapeutics has acquired 1 company.
What was the largest acquisition by Sangamo Therapeutics?$78M acquisition of TxCell on 23rd July 2018 was the largest M&A Sangamo Therapeutics has done to date.
What companies Sangamo Therapeutics acquired?Sangamo Therapeutics acquired TxCell.
In how many companies Sangamo Therapeutics has invested to date?Sangamo Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Sangamo Therapeutics

Lists including Sangamo Therapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial